Fontolizumab

Fontolizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	interferon gamma
Clinical data
ATC code	none
Identifiers
CAS Number	326859-36-3^N
ChemSpider	none
UNII	6J92H2439Z
KEGG	D04242^Y
Chemical and physical data
Molar mass	ca. 150 kg/mol
^NY (what is this?)  (verify)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody^[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.^[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.^[3]

References

1. Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
2. Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010). "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. S2CID 25337474.
3. Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov